UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 2, 2016
GEMPHIRE THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware | | 001-37809 | | 47-2389984 |
(State or other jurisdiction
of incorporation) | | (Commission
File No.) | | (IRS Employer
Identification No.) |
17199 N. Laurel Park Drive, Suite 401
Livonia, Michigan 48152
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (248) 681-9815
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On November 2, 2016, Gemphire Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the third quarter ended September 30, 2016. The press release is furnished as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | | Description |
| | |
99.1 | | Press Release dated November 2, 2016 reporting financial results for the third quarter ended September 30, 2016. |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | GEMPHIRE THERAPEUTICS INC. |
| | | |
Dated: November 2, 2016 | | | |
| | | |
| | By: | /s/ Jeffrey S. Mathiesen |
| | | Jeffrey S. Mathiesen |
| | | Chief Financial Officer |
3
EXHIBIT INDEX
Exhibit | | Description |
| | |
99.1 | | Press Release dated November 2, 2016 reporting financial results for the third quarter ended September 30, 2016. |
4
